Abstract
The histomorphological subtyping of papillary renal cell carcinomas (pRCCs) has improved the predictions of patients’ long-term survival. Based on our previous results, we hypothesized that the MYC proto-oncogene would show differential expression in pRCC subtypes. Using a multi-institutional cohort of 204 pRCC patients we assessed the additional value of the immunohistochemical markers MYC, MINA53, and Ki67 in predicting patient’s long-term survival. The clinical endpoints were overall survival (OS) and cancer-specific survival (CSS). Nomograms were constructed to predict each patient’s risk of death (OS). The incorporation of the MYC staining patterns allowed the stratification of pRCC type 1 patients into better and worse prognostic groups. None of the patients with pRCC type 1 tumors and favorable MYC staining patterns died from tumor-related causes. This prognostic value was independent of the patient’s age at surgery, the pathological tumor stage and presence of lymph node invasion. we could show that the immunohistochemical assessment of MYC and the histomorphological subtyping of pRCC stratifies pRCC type 1 tumors with regard to OS and CSS. The determination of the histomorphologic pRCC subtype in combination with the MYC immunohistochemical staining patterns allows a more accurate prediction of patients’ individual risk of death.
Highlights
With an estimated 338,000 new cases in 2012, renal cell carcinoma (RCC) accounts for 2.4% of all cancer cases worldwide[1]
A total of 204 patients with papillary RCC were included in this study: 113 patients with papillary renal cell carcinomas (pRCCs) type 1, 39 patients with pRCC type 2, and 34 patients with mixed-histology pRCCs
We discovered that only myelocytomatosis viral oncogene homolog (MYC), but not the MINA53 or Ki67 staining patterns, was able to further sub-stratify the cohort of pRCC type 1 tumors
Summary
With an estimated 338,000 new cases in 2012, renal cell carcinoma (RCC) accounts for 2.4% of all cancer cases worldwide[1]. In addition to the conventional clear cell RCC, papillary RCC (pRCC) is the second most common subtype, which represents 10–15% of all RCCs3,4. Based on their histomorphological characteristics, pRCCs can further be sub-classified into two distinct subtypes[5]. The miRNA expression patterns are highly specific and are able to discriminate between different tumor entities[10], and even between different RCC subtypes[11]. We identified miRNAs, miR-210 and let-7c, which were able to discriminate between the two distinct pRCC subtypes with high accuracy. MYC under the control of the γ-glutamyl transferase promoter induced RCCs that resembled human collecting duct carcinomas[16], while MYC under control of the Cadherin-16 promoter induced high-grade papillary tumors[17]. The aim of the present study was to assess the additional value of the immunohistochemical markers MYC, MINA53, and Ki67 in predicting patient’s long-term survival
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
